Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML

In this week’s episode, we'll discuss how patients with relapsed or refractory Hodgkin lymphoma survival outcomes have improved after development of several novel agents. Next, precision engineering of therapeutic T cells through extragenic safe harbors. Finally, using a single-cell atlas to map features of imatinib resistance in diagnostic CML bone marrow, investigators present gene expression signatures predictive of response to TKI therapy.

What is Blood Podcast?

Stay up to date on the latest research and reviews for both clinical and basic hematology with Blood podcast, published weekly in conjunction with each issue of Blood. Additionally, Blood review series podcasts feature in depth discussion with authors of recently published review articles. Subscribe and never miss a new episode.